Page last updated: 2024-10-28

hydralazine and Parkinson Disease

hydralazine has been researched along with Parkinson Disease in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Mehrabani, M1
Nematollahi, MH1
Tarzi, ME1
Juybari, KB1
Abolhassani, M1
Sharifi, AM1
Paseban, H1
Saravani, M1
Mirzamohammadi, S1

Other Studies

1 other study available for hydralazine and Parkinson Disease

ArticleYear
Protective effect of hydralazine on a cellular model of Parkinson's disease: a possible role of hypoxia-inducible factor (HIF)-1α.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2020, Volume: 98, Issue:3

    Topics: Antioxidants; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dopamine; Humans; Hydralazin

2020